Obesity Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Empros Pharma, ERX Pharma, Raziel, Novo Nordisk, Saniona, Eli Lilly

Obesity Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Empros Pharma, ERX Pharma, Raziel, Novo Nordisk, Saniona, Eli Lilly
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Obesity therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Obesity Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Obesity Market. 

The Obesity Pipeline report embraces in-depth commercial, regulatory, and Obesity clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Obesity drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Obesity Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Obesity treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Obesity therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Obesity companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Obesity drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Obesity therapeutic market.

Obesity Therapeutics Landscape

Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances. The FDA has approved several prescription medications for weight loss management in the overweight and obese patient population. 

The US FDA has approved XENICAL (orlistat), QSYMIA (phentermine-topiramate), CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), and IMCIVREE (setmelanotide)—for long-term use in overweight and obesity treatment. These therapies work by blocking the absorption of macronutrients; decreasing energy intake, and increasing energy expenditure.

To further improve the treatment outlook, there are approx. 100+ key companies developing therapies for Obesity. Currently, Novo Nordisk is leading the therapeutics market with its Obesity drug candidates in the most advanced stage of clinical development.

Obesity Companies Actively Working in the Therapeutic Market Include:

180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, BioRestorative Therapies, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd., Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and many others

Emerging and Marketed Obesity Drugs Covered in the Report Include:

  • CT-868: Carmot Therapeutics

  • DD01: D&D Pharmatech

  • EMP16: Empros Pharma

  • ERX-1000: ERX Pharmaceuticals

  • RZL-012: Raziel Therapeutics

  • Semaglutide oral: Novo Nordisk

  • Tesomet: Saniona

  • Tirzepatide: Eli Lilly and Company

  • ZP 8396: Zealand Pharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Obesity Companies Working in the Market @


Analysis of Emerging Obesity Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical.

Molecule Type

Obesity Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Obesity Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Obesity Treatment Patterns

4. Obesity – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Obesity Late Stage Products (Phase-III)

7. Obesity Mid-Stage Products (Phase-II)

8. Obesity Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Obesity Discontinued Products

13. Obesity Product Profiles

14. Major Obesity Companies in the Market

15. Key Products in the Obesity Therapeutics Segment

16. Dormant and Discontinued Products

17. Obesity Unmet Needs

18. Obesity Future Perspectives

19. Obesity Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Peptic Ulcers Market

“Peptic Ulcers Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Peptic Ulcers market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Peptic Ulcers market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology